Understand the source comparison
SS-LUP-332 SubQ vs IM Injection Route: Administration Comparison
Subcutaneous (SubQ) 4–6 92% Low (minimal IL-6/TNF-α elevation) Long-duration metabolic studies, sustained PPAR activation, chronic dosing protocols Once daily Preferred for multi-week studies where sustained receptor occupancy matters more than rapid onset; lo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Subcutaneous (SubQ)
- 4–6
- 92%
- Low (minimal IL-6/TNF-α elevation)
- Long-duration metabolic studies, sustained PPAR activation, chronic dosing protocols
- Once daily
- Preferred for multi-week studies where sustained receptor occupancy matters more than rapid onset; lower tissue trauma supports consistent absorption over time
- Intramuscular (IM)
- 1.5–2
- 88%
- Moderate to High (measurable cytokine spike at injection site)
- Acute metabolic response studies, rapid glucose uptake measurement, short-term protocols
- Twice daily for sustained levels
- Faster peak makes it viable for studies measuring immediate metabolic flux, but inflammatory confounding limits use in immune-metabolic research
- Intraperitoneal (IP)
- 0.5–1
- 95%
- High (peritoneal immune activation)
- Rarely used for SS-LUP-332; included for reference only
- Variable
- Not recommended. Absorption too rapid for PPAR-mediated transcriptional studies and introduces significant immune activation